Name | 5-Fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]-4,6-pyrimidinediamine |
---|---|
Synonyms |
5-Fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N-[4-(trifluoromethyl)phenyl]-4,6-pyrimidinediamine
4,6-Pyrimidinediamine, 5-fluoro-2-(6-fluoro-2-methyl-1H-benzimidazol-1-yl)-N4-[4-(trifluoromethyl)phenyl]- |
Description | PTC596 is an orally active and selective B-cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) inhibitor. PTC596 targets BMI1 expressed by both tumor cells and cancer stem cells (CSCs), and induces hyper-phosphorylation of BMI1, leading to its degradation. PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells[1][2]. |
---|---|
Related Catalog | |
Target |
BMI-1[1] |
References |
Density | 1.6±0.1 g/cm3 |
---|---|
Boiling Point | 583.9±60.0 °C at 760 mmHg |
Molecular Formula | C19H13F5N6 |
Molecular Weight | 420.339 |
Flash Point | 307.0±32.9 °C |
Exact Mass | 420.112183 |
LogP | 3.68 |
Vapour Pressure | 0.0±1.6 mmHg at 25°C |
Index of Refraction | 1.645 |